INFI Annual CFF
$73.00 K
-$87.03 M-99.92%
31 December 2022
Summary:
As of January 21, 2025, INFI annual cash flow from financing activities is $73.00 thousand, with the most recent change of -$87.03 million (-99.92%) on December 31, 2022. During the last 3 years, it has fallen by -$27.66 million (-99.74%).INFI Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI Quarterly CFF
$16.00 K
0.00%
30 June 2023
Summary:
As of January 21, 2025, INFI quarterly cash flow from financing activities is $16.00 thousandOver the past year, it has dropped by -$12.00 thousand (-42.86%).INFI Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI TTM CFF
$61.00 K
0.00%
30 June 2023
Summary:
As of January 21, 2025, INFI TTM cash flow from financing activities is $61.00 thousandOver the past year, it has dropped by -$869.00 thousand (-93.44%).INFI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -99.9% | -42.9% | -93.4% |
| 3 y3 years | -99.7% | -46.7% | -99.7% |
| 5 y5 years | +150.0% | -99.7% | -99.8% |
INFI Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -100.0% | -100.0% | -100.0% |
Infinity Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $16.00 K(-48.4%) | $61.00 K(-16.4%) |
| Dec 2022 | $73.00 K(-99.9%) | $31.00 K(+121.4%) | $73.00 K(-81.7%) |
| Sept 2022 | - | $14.00 K(-50.0%) | $398.00 K(-57.2%) |
| June 2022 | - | $28.00 K(-92.1%) | $930.00 K(-98.9%) |
| Dec 2021 | $87.11 M(+217.4%) | $356.00 K(-34.8%) | $87.11 M(-1.1%) |
| Sept 2021 | - | $546.00 K(+680.0%) | $88.11 M(-6.3%) |
| June 2021 | - | $70.00 K(-99.9%) | $94.04 M(+0.0%) |
| Mar 2021 | - | $86.13 M(+6252.0%) | $94.00 M(+242.6%) |
| Dec 2020 | $27.44 M(-1.0%) | $1.36 M(-79.1%) | $27.44 M(+5.0%) |
| Sept 2020 | - | $6.48 M(>+9900.0%) | $26.13 M(+32.7%) |
| June 2020 | - | $30.00 K(-99.8%) | $19.69 M(+0.0%) |
| Mar 2020 | - | $19.57 M(>+9900.0%) | $19.68 M(-29.0%) |
| Dec 2019 | $27.73 M(+393.5%) | $47.00 K(+23.7%) | $27.73 M(+0.0%) |
| Sept 2019 | - | $38.00 K(+40.7%) | $27.73 M(+0.2%) |
| June 2019 | - | $27.00 K(-99.9%) | $27.67 M(-18.1%) |
| Mar 2019 | - | $27.62 M(>+9900.0%) | $33.80 M(+501.5%) |
| Dec 2018 | $5.62 M(-3948.6%) | $42.00 K(-362.5%) | $5.62 M(-0.7%) |
| Sept 2018 | - | -$16.00 K(-100.3%) | $5.66 M(+1.2%) |
| June 2018 | - | $6.16 M(-1193.4%) | $5.59 M(-1030.9%) |
| Mar 2018 | - | -$563.00 K(-770.2%) | -$601.00 K(+311.6%) |
| Dec 2017 | -$146.00 K(+75.9%) | $84.00 K(-202.4%) | -$146.00 K(-68.6%) |
| Sept 2017 | - | -$82.00 K(+105.0%) | -$465.00 K(-4.7%) |
| June 2017 | - | -$40.00 K(-63.0%) | -$488.00 K(+269.7%) |
| Mar 2017 | - | -$108.00 K(-54.0%) | -$132.00 K(+59.0%) |
| Dec 2016 | -$83.00 K(-103.6%) | -$235.00 K(+123.8%) | -$83.00 K(-113.3%) |
| Sept 2016 | - | -$105.00 K(-133.2%) | $622.00 K(-14.0%) |
| June 2016 | - | $316.00 K(-635.6%) | $723.00 K(-34.3%) |
| Mar 2016 | - | -$59.00 K(-112.6%) | $1.10 M(-52.6%) |
| Dec 2015 | $2.32 M(-37.7%) | $470.00 K(<-9900.0%) | $2.32 M(-37.0%) |
| Sept 2015 | - | -$4000.00(-100.6%) | $3.68 M(+3.2%) |
| June 2015 | - | $693.00 K(-40.4%) | $3.57 M(+21.8%) |
| Mar 2015 | - | $1.16 M(-36.6%) | $2.93 M(-21.2%) |
| Dec 2014 | $3.72 M(-34.4%) | $1.83 M(-1666.7%) | $3.72 M(+23.4%) |
| Sept 2014 | - | -$117.00 K(-312.7%) | $3.02 M(-25.5%) |
| June 2014 | - | $55.00 K(-97.2%) | $4.05 M(-21.3%) |
| Mar 2014 | - | $1.95 M(+73.0%) | $5.15 M(-9.2%) |
| Dec 2013 | $5.67 M(-98.1%) | $1.13 M(+23.0%) | $5.67 M(-96.8%) |
| Sept 2013 | - | $917.00 K(-20.4%) | $179.05 M(-39.1%) |
| June 2013 | - | $1.15 M(-53.5%) | $294.11 M(-0.5%) |
| Mar 2013 | - | $2.48 M(-98.6%) | $295.46 M(+0.6%) |
| Dec 2012 | $293.68 M(+480.7%) | $174.51 M(+50.5%) | $293.68 M(+73.5%) |
| Sept 2012 | - | $115.97 M(+4531.4%) | $169.30 M(+215.7%) |
| June 2012 | - | $2.50 M(+260.8%) | $53.63 M(+4.6%) |
| Mar 2012 | - | $694.00 K(-98.6%) | $51.26 M(+1.4%) |
| Dec 2011 | $50.58 M | $50.13 M(>+9900.0%) | $50.58 M(+9770.6%) |
| Sept 2011 | - | $309.00 K(+132.3%) | $512.40 K(+68.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2011 | - | $133.00 K(+1562.5%) | $304.50 K(+30.8%) |
| Mar 2011 | - | $8000.00(-87.2%) | $232.80 K(-0.9%) |
| Dec 2010 | $235.00 K(-98.0%) | $62.40 K(-38.3%) | $235.00 K(+27.8%) |
| Sept 2010 | - | $101.10 K(+64.9%) | $183.90 K(+70.6%) |
| June 2010 | - | $61.30 K(+501.0%) | $107.80 K(+314.6%) |
| Mar 2010 | - | $10.20 K(-9.7%) | $26.00 K(-99.8%) |
| Dec 2009 | $11.97 M(-45.6%) | $11.30 K(-54.8%) | $11.97 M(-64.5%) |
| Sept 2009 | - | $25.00 K(-222.0%) | $33.71 M(+0.2%) |
| June 2009 | - | -$20.50 K(-100.2%) | $33.64 M(+0.3%) |
| Mar 2009 | - | $11.95 M(-45.1%) | $33.53 M(+52.3%) |
| Dec 2008 | $22.02 M(-2176.8%) | $21.76 M(<-9900.0%) | $22.02 M(>+9900.0%) |
| Sept 2008 | - | -$45.10 K(-65.9%) | $65.70 K(-140.0%) |
| June 2008 | - | -$132.30 K(-130.3%) | -$164.20 K(-45.5%) |
| Mar 2008 | - | $436.90 K(-325.4%) | -$301.20 K(-71.6%) |
| Dec 2007 | -$1.06 M(-102.5%) | -$193.80 K(-29.5%) | -$1.06 M(-93.5%) |
| Sept 2007 | - | -$275.00 K(+2.1%) | -$16.34 M(-170.5%) |
| June 2007 | - | -$269.30 K(-16.3%) | $23.16 M(-28.7%) |
| Mar 2007 | - | -$321.90 K(-97.9%) | $32.49 M(-21.9%) |
| Dec 2006 | $41.61 M(-1312.7%) | -$15.47 M(-139.4%) | $41.61 M(-25.6%) |
| Sept 2006 | - | $39.22 M(+332.8%) | $55.96 M(+292.0%) |
| June 2006 | - | $9.06 M(+3.0%) | $14.28 M(+174.0%) |
| Mar 2006 | - | $8.80 M(-888.0%) | $5.21 M(-251.9%) |
| Dec 2005 | -$3.43 M(-113.8%) | -$1.12 M(-54.7%) | -$3.43 M(-120.2%) |
| Sept 2005 | - | -$2.47 M(>+9900.0%) | $16.94 M(-13.7%) |
| June 2005 | - | -$2400.00(-101.6%) | $19.64 M(-20.7%) |
| Mar 2005 | - | $153.30 K(-99.2%) | $24.78 M(-0.6%) |
| Dec 2004 | $24.93 M(-4031.4%) | $19.26 M(+8233.9%) | $24.93 M(+313.4%) |
| Sept 2004 | - | $231.10 K(-95.5%) | $6.03 M(+13.5%) |
| June 2004 | - | $5.14 M(+1642.2%) | $5.31 M(+3712.5%) |
| Mar 2004 | - | $295.00 K(-18.8%) | $139.30 K(-122.0%) |
| Dec 2003 | -$634.00 K(+3.9%) | $363.30 K(-174.6%) | -$633.90 K(-43.7%) |
| Sept 2003 | - | -$487.00 K(+1421.9%) | -$1.13 M(+3.5%) |
| June 2003 | - | -$32.00 K(-93.3%) | -$1.09 M(-42.4%) |
| Mar 2003 | - | -$478.20 K(+271.9%) | -$1.89 M(+209.6%) |
| Dec 2002 | -$610.20 K(-227.9%) | -$128.60 K(-71.4%) | -$610.30 K(-56.3%) |
| Sept 2002 | - | -$449.20 K(-46.1%) | -$1.40 M(+639.3%) |
| June 2002 | - | -$833.50 K(-204.1%) | -$189.10 K(-114.5%) |
| Mar 2002 | - | $801.00 K(-187.4%) | $1.30 M(+172.9%) |
| Dec 2001 | $477.00 K(-99.5%) | -$916.30 K(-220.6%) | $476.90 K(-68.0%) |
| Sept 2001 | - | $759.70 K(+15.6%) | $1.49 M(-98.4%) |
| June 2001 | - | $657.20 K(-2873.0%) | $93.80 M(-4.2%) |
| Mar 2001 | - | -$23.70 K(-124.4%) | $97.93 M(-2.5%) |
| Dec 2000 | $100.45 M(+2543.9%) | $97.30 K(-99.9%) | $100.45 M(+0.1%) |
| Sept 2000 | - | $93.07 M(+1842.4%) | $100.36 M(+1276.6%) |
| June 2000 | - | $4.79 M(+91.7%) | $7.29 M(+191.7%) |
| Mar 2000 | - | $2.50 M | $2.50 M |
| Dec 1999 | $3.80 M | - | - |
FAQ
- What is Infinity Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals annual CFF year-on-year change?
- What is Infinity Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals quarterly CFF year-on-year change?
- What is Infinity Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals TTM CFF year-on-year change?
What is Infinity Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of INFI is $73.00 K
What is the all time high annual CFF for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high annual cash flow from financing activities is $293.68 M
What is Infinity Pharmaceuticals annual CFF year-on-year change?
Over the past year, INFI annual cash flow from financing activities has changed by -$87.03 M (-99.92%)
What is Infinity Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of INFI is $16.00 K
What is the all time high quarterly CFF for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high quarterly cash flow from financing activities is $174.51 M
What is Infinity Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, INFI quarterly cash flow from financing activities has changed by -$12.00 K (-42.86%)
What is Infinity Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of INFI is $61.00 K
What is the all time high TTM CFF for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high TTM cash flow from financing activities is $295.46 M
What is Infinity Pharmaceuticals TTM CFF year-on-year change?
Over the past year, INFI TTM cash flow from financing activities has changed by -$869.00 K (-93.44%)